- Home
- MRSN vs IHD Comparison
MRSN vs IHD Comparison
Compare MRSN & IHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- IHD
- Stock Information
- Founded
- MRSN 2001
- IHD 2011
- Country
- MRSN United States
- IHD United States
- Employees
- MRSN N/A
- IHD N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- IHD Investment Managers
- Sector
- MRSN Health Care
- IHD Finance
- Exchange
- MRSN Nasdaq
- IHD Nasdaq
- Market Cap
- MRSN 71.9M
- IHD 89.7M
- IPO Year
- MRSN 2017
- IHD N/A
- Fundamental
- Price
- MRSN $0.48
- IHD $5.35
- Analyst Decision
- MRSN Buy
- IHD
- Analyst Count
- MRSN 4
- IHD 0
- Target Price
- MRSN $4.33
- IHD N/A
- AVG Volume (30 Days)
- MRSN 3.8M
- IHD 27.7K
- Earning Date
- MRSN 03-03-2025
- IHD 01-01-0001
- Dividend Yield
- MRSN N/A
- IHD 10.32%
- EPS Growth
- MRSN N/A
- IHD N/A
- EPS
- MRSN N/A
- IHD N/A
- Revenue
- MRSN $40,497,000.00
- IHD N/A
- Revenue This Year
- MRSN N/A
- IHD N/A
- Revenue Next Year
- MRSN $67.68
- IHD N/A
- P/E Ratio
- MRSN N/A
- IHD N/A
- Revenue Growth
- MRSN 9.88
- IHD N/A
- 52 Week Low
- MRSN $0.45
- IHD $4.49
- 52 Week High
- MRSN $5.96
- IHD $5.47
- Technical
- Relative Strength Index (RSI)
- MRSN 35.88
- IHD 52.70
- Support Level
- MRSN $0.49
- IHD $5.22
- Resistance Level
- MRSN $0.56
- IHD $5.45
- Average True Range (ATR)
- MRSN 0.05
- IHD 0.09
- MACD
- MRSN 0.02
- IHD -0.01
- Stochastic Oscillator
- MRSN 28.11
- IHD 40.63
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.